SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation D50W

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Sleep, Obesity, and Metabolism in Normal and Overweight Subjects: Effects of CPAP on Glucose Metabolism

Obstructive sleep apnea affects approximately 2-4% of middle-aged adults in the general population and is associated with several medical conditions including hypertension and coronary artery. Research over the last decade has shown that obstructive sleep apnea may also increase the propensity for insulin resistance, glucose intolerance, and type 2 diabetes mellitus. Positive airway pressure (PAP) is the first line therapy for the treatment of obstructive sleep apnea. While PAP therapy has several favorable effects such as improvements in daytime sleepiness and quality of life, it is not clear whether using PAP therapy can alter metabolic risk. The overall objective of this study is to examine whether treatment of obstructive sleep apnea with positive airway pressure therapy improves glucose tolerance and insulin sensitivity. The primary hypothesis of this study is that PAP therapy of obstructive sleep apnea will improve in insulin sensitivity and glucose metabolism.

NCT01503164 Obstructive Sleep Apnea Sleep Apnea Sleep-disordered Breathing Device: Positive Pressure Therapy (PAP) Behavioral: LifeStyle Counseling
MeSH:Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiratory Aspiration
HPO:Apnea Obstructive sleep apnea Sleep apnea

This test requires administration of a weight-adjusted dose of D50W as an IV bolus at time "zero". --- D50W ---

Primary Outcomes

Description: Insulin sensitivity will be determined with the insulin-modified frequently sampled intravenous glucose tolerance test (IVGTT) before and 2-months after study intervention. This test requires administration of a weight-adjusted dose of D50W as an IV bolus at time "zero". After the glucose bolus, blood samples are drawn at the scheduled times for 3-hours. At the 20-minute mark, a weight-adjusted dose of regular insulin is administered. The resulting serum is analyzed for glucose and insulin and the "minimal model" (MINMOD) will be used to derive insulin sensitivity. A low SI signifies low insulin sensitivity and high SI represents high insulin sensitivity.

Measure: Insulin Sensitivity (SI)

Time: Baseline

Description: Insulin sensitivity will be determined with the insulin-modified frequently sampled intravenous glucose tolerance test (IVGTT) before and 2-months after study intervention. This test requires administration of a weight-adjusted dose of D50W as an IV bolus at time "zero". After the glucose bolus, blood samples are drawn at the scheduled times for 3-hours. At the 20-minute mark, a weight-adjusted dose of regular insulin is administered. The resulting serum is analyzed for glucose and insulin and the "minimal model" (MINMOD) will be used to derive insulin sensitivity. A low SI signifies low insulin sensitivity and high SI represents high insulin sensitivity.

Measure: Insulin Sensitivity (SI)

Time: 2 months after intervention

Secondary Outcomes

Description: Glucose effectiveness is the ability for glucose to move intracellularly in the absence of insulin. It is a parameter that results from the MINMOD analysis of the serum glucose and insulin levels derived from the frequently sampled intravenous glucose tolerance test. Low SG indicates a lower predisposition for glucose disposal independent of any effects of insulin.

Measure: Glucose Effectiveness (SG)

Time: Baseline

Description: Glucose effectiveness is the ability for glucose to move intracellularly in the absence of insulin. It is a parameter that results from the MINMOD analysis of the serum glucose and insulin levels derived from the frequently sampled intravenous glucose tolerance test. Low SG indicates a lower predisposition for glucose disposal independent of any effects of insulin.

Measure: Glucose Effectiveness (SG)

Time: 2 months after intervention

Description: The disposition index is the mathematical product of insulin sensitivity (SI) and acute insulin response to glucose (AIRG) both of which are derived from the MINMOD analysis of the frequently sampled intravenous glucose tolerance test data. A low DI is indicative of a higher risk of developing diabetes.

Measure: Disposition Index (DI)

Time: Baseline

Description: The disposition index is the mathematical product of insulin sensitivity (SI) and acute insulin response to glucose (AIRG) both of which are derived from the MINMOD analysis of the frequently sampled intravenous glucose tolerance test data.

Measure: Disposition Index (DI)

Time: 2 months after intervention

Description: The acute insulin response to glucose (AIRG) value is derived from the MINMOD analysis of the glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test. A low AIRG indicates decreased ability of the pancreas to secrete insulin.

Measure: Acute Insulin Response to Glucose (AIRG)

Time: Baseline

Description: The acute insulin response to glucose (AIRG) value is derived from the MINMOD analysis of the glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test. A low AIRG indicates decreased ability of the pancreas to secrete insulin.

Measure: Acute Insulin Response to Glucose (AIRG)

Time: 2 months after intervention

Description: Endothelial function will be assessed using peripheral arterial tonometry using the Endo-PAT device. Using the EndoPat device, the relative vasoconstriction of occluded versus non-occluded arms was derived and provided the relative hyperemic index.

Measure: Endothelial Function

Time: Baseline

Description: Endothelial function will be assessed using peripheral arterial tonometry using the Endo-PAT device. Using the EndoPat device, the relative vasoconstriction of occluded versus non-occluded arms was derived and provided the relative hyperemic index.

Measure: Endothelial Function

Time: 2 month after intervention

Description: Results of the oral glucose tolerance test will be analyzed using indices derived from the serial glucose and insulin levels over the 2 hour period. This will be the area under the glucose/ insulin curves

Measure: Area Under the Curve Assessed by Oral Glucose Tolerance Test

Time: Baseline

Description: Results of the oral glucose tolerance test will be analyzed using indices derived from the serial glucose and insulin levels over a 2 hour period 2 months post intervention. This will be the area under the glucose/ insulin curves

Measure: Area Under the Curve Assessed by Oral Glucose Tolerance Test (OGTT)

Time: 2 month after intervention


HPO Nodes


HP:0002104: Apnea
Genes 318
TWIST1 LIFR SCN2A GBA NALCN CCDC47 NDUFS1 TMEM231 NDUFAF6 LIPT1 NEFH CTSD GLRA1 GLUL VAMP1 TMEM237 TRPV4 NDUFB8 TCTN3 AFF4 NGLY1 FGFR3 TCF4 SLC6A9 NDUFV1 NDUFS8 PLPBP RPS6KA3 NEB GABRG2 NADK2 KIAA0586 CTNNB1 ECHS1 NDUFA13 PWAR1 SURF1 PCCB PHOX2B ECHS1 NDUFS7 AMER1 TMEM138 PRPH GNE GPR101 LTBP3 SH3BP2 HSPG2 DNA2 NPHP1 ACY1 CSPP1 BRAF PET100 CHRNE PLCB4 NDUFAF2 SLC5A7 B9D1 ND1 BMP2 SLC39A8 COLQ NPAP1 TRIP13 CC2D2A GPR101 GABBR2 PHOX2B P4HTM RARS2 HRAS SCO2 NDUFS2 RET HTRA2 CEP57 USP7 COQ2 INPP5E COL13A1 TMEM107 ZC4H2 TCTN2 TMEM67 PCCA KATNIP NEK1 CRYAB COQ2 AIP KIF5A NDUFAF5 C2CD3 ATP6 GDNF SKI SFTPB NFIX BUB3 GNAI3 RPGRIP1L FLCN ARL3 SCN4A KIAA0586 SLC25A20 RERE TCIRG1 INPP5E NDN TBR1 LIFR NDUFV1 TNFSF11 TCTN1 NDUFA11 TSEN54 DST FOXRED1 ASCL1 CEP120 SLC18A3 ASCL1 SNX10 CEP290 CISD2 CPLANE1 CHAT MYO9A TOE1 CLCN7 TSPYL1 SOX9 MKS1 SDHA AHI1 ARL13B FBP1 TMEM216 HERC2 FARS2 MAGEL2 TECPR2 EDN1 NONO CEP104 ND5 CSPP1 LARP7 LIAS KIAA0586 ZNF423 SNORD115-1 RPGRIP1L SLC19A3 NDUFAF2 TMEM237 MKRN3-AS1 MYO9A RBM10 SCN5A TACO1 TMEM216 CEP57 MECP2 PLCB4 ATN1 GNE AGRN FAM149B1 KCNQ2 INPP5E FGFR3 CEP41 SNAP25 SYT1 GPHN INPP5E CC2D2A MCCC1 EP300 SLC2A1 NDUFA12 PIGT ARMC9 NDUFV2 NDUFS8 SRPX2 UNC80 GNPTAB SNRPN BRAT1 FGFR3 POGZ ACADSB GRIN2A SURF1 PTF1A FGFR2 D2HGDH TMEM237 KIF7 PLAA CEP120 KIAA0753 PEX5 AHI1 PCGF2 DMPK TSPYL1 BTD GBA CEP41 PCK1 SOD1 DKK1 ATP5F1A SYT1 RNF125 NDUFA2 SLC6A5 WFS1 CEP290 CREBBP IDS MKRN3 PRNP EDN3 TMEM67 RPGRIP1L IDUA ARCN1 SLC25A1 PDHA1 KAT6B BUB1B SCN4A DPH1 GSN GNAI3 FBP1 SNORD116-1 PRPS1 COX15 HMGCL PIBF1 NDUFS3 NDUFS2 ND4 NDUFS4 PEX13 OPA1 CHAT NDUFA10 TRNL1 NDUFS1 TMEM216 ND3 SLC5A7 ALPL CPT2 SLC18A3 TRNK TRNW MTFMT ND6 PWRN1 BUB1 ND2 USP7 NDUFA2 NACC1 BRAT1 CSPP1 PIBF1 AHDC1 NDUFAF3 FGFR3 PSAP DNA2 AHDC1 OFD1 RUNX2 NDUFA4 TRNV RET NGLY1 FBN1 DPAGT1 TCF4 MAGEL2 AHI1 MECP2 IPW SKI PDHA1 CPLANE1 ABCA3 RAI1 FGFR2 SYT2 NDUFA9 BTD LAMB2 PRMT7 HYLS1 MKS1 TECPR2 IDUA HSPD1 PDE6D PLAA FXR1 ARMC9 COL3A1 DCTN1